S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Insulet Stock Forecast, Price & News

+8.52 (+3.91%)
(As of 07/1/2022 08:45 PM ET)
Today's Range
50-Day Range
52-Week Range
258,500 shs
Average Volume
602,185 shs
Market Capitalization
$15.70 billion
P/E Ratio
Dividend Yield
Price Target

Insulet MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
28.2% Upside
$290.36 Price Target
Short Interest
4.69% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.36mentions of Insulet in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$5.39 M Sold Last Quarter
Proj. Earnings Growth
From $1.30 to $1.79 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.25 out of 5 stars

Medical Sector

225th out of 1,412 stocks

Surgical & Medical Instruments Industry

26th out of 136 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

Insulet logo

About Insulet (NASDAQ:PODD) Stock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock News Headlines

Comparing Penumbra (NYSE:PEN) and Insulet (NASDAQ:PODD)
Brokerages Set Insulet Co. (NASDAQ:PODD) PT at $290.17
Why Insulet Stock Is Soaring This Week
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$16.80 million
Pretax Margin


Sales & Book Value

Annual Sales
$1.10 billion
Cash Flow
$1.08 per share
Book Value
$8.07 per share


Free Float
Market Cap
$15.70 billion

Social Links

Insulet Frequently Asked Questions

Should I buy or sell Insulet stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Insulet stock.
View analyst ratings for Insulet
or view top-rated stocks.

What is Insulet's stock price forecast for 2022?

10 Wall Street research analysts have issued 12-month price targets for Insulet's stock. Their PODD stock forecasts range from $230.00 to $350.00. On average, they predict Insulet's share price to reach $290.36 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

How has Insulet's stock price performed in 2022?

Insulet's stock was trading at $266.07 at the beginning of the year. Since then, PODD stock has decreased by 14.9% and is now trading at $226.46.
View the best growth stocks for 2022 here

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Insulet

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, May, 5th. The medical instruments supplier reported $0.40 EPS for the quarter, topping the consensus estimate of $0.23 by $0.17. The medical instruments supplier earned $295.40 million during the quarter, compared to analyst estimates of $287.99 million. Insulet had a net margin of 3.91% and a trailing twelve-month return on equity of 15.81%. The firm's revenue was up 17.1% compared to the same quarter last year.
View Insulet's earnings history

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.23 billion-$1.27 billion, compared to the consensus revenue estimate of $1.24 billion.

Who are Insulet's key executives?

Insulet's management team includes the following people:

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $226.46.

How much money does Insulet make?

Insulet (NASDAQ:PODD) has a market capitalization of $15.70 billion and generates $1.10 billion in revenue each year. The medical instruments supplier earns $16.80 million in net income (profit) each year or $0.629990 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 2,300 workers across the globe.

When was Insulet founded?

Insulet was founded in 2000.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The official website for Insulet is www.insulet.com. The medical instruments supplier can be reached via phone at (978) 600-7000, via email at ir@insulet.com, or via fax at 978-600-0120.

This page (NASDAQ:PODD) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.